Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APL-1202 vs Epirubicin in Naïve Intermediate-Risk NMIBC
NCT04736394Phase 3Recruiting
- Sponsor
- Asieris Pharmaceuticals
- Start
- Sep 2021
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of APL-1202 + APL-1501 in non-muscle-invasive bladder cancer (NMIBC), sponsored by Asieris Pharmaceuticals. Started Sep 2021; status: recruiting.
02
Drugs
APL-1202 + APL-1501
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT04736394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04736394.